The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26061247 |
71 |
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. |
The University of Texas M.D. Anderson Cancer Center |
| 25974391 |
78 |
Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. |
University of Oxford |
| 26080064 |
141 |
Structure-Based Design of¿-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. |
University of Michigan |
| 25249180 |
146 |
The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. |
Glaxosmithkline |
| 27757418 |
27 |
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. |
University of Oxford |
| 32453591 |
70 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. |
University of Illinois At Chicago |
| 27219867 |
94 |
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. |
Genentech |
| 30606676 |
83 |
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor. |
Gilead Sciences |
| 24313754 |
43 |
[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. |
University of Oxford |
| 29902720 |
80 |
Structure-based discovery of selective BRPF1 bromodomain inhibitors. |
University of Zurich |
| 29656650 |
151 |
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. |
University of Strathclyde |
| 29169673 |
115 |
Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300. |
Wuxi Apptec |
| 28463487 |
185 |
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. |
University of Michigan |
| 30015487 |
96 |
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. |
TBA |
| 29448139 |
117 |
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. |
Guangzhou Medical University |
| 28268136 |
130 |
Methylpyrrole inhibitors of BET bromodomains. |
Abbvie |
| 29155580 |
65 |
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors. |
Genentech |
| 28949521 |
88 |
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. |
Abbvie |
| 28849908 |
13 |
Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation. |
Oxford University |
Search and Browse
